GlassScriptPhysician profile
Erick A Salvatierra
NPI 1508067653
$27,018.99
in general payments reported to CMS, 2019-2025
32 companies · $23K in 2025
The $23K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $329 · 2021: $413 · 2022: $522 · 2023: $700 · 2024: $682 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $2,629 · Travel and Lodging: $1,270 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,964.50 |
| Food and Beverage | $2,629.49 |
| Travel and Lodging | $1,269.81 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $22,813.76 | 2025 | Rezdiffra |
| Abbvie INC. | $1,317.43 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $412.11 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $359.36 | 2020-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $333.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.47 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Celgene Corporation | $216.26 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $200.63 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $120.06 | 2019 | |
| Medtronic, INC. | $116.83 | 2021 | |
| Daiichi Sankyo INC. | $112.96 | 2019-2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $91.30 | 2020-2024 | Linzess |
| Romark Laboratories, Lc | $89.36 | 2019-2020 | |
| Genzyme Corporation | $82.90 | 2024-2025 | |
| Ardelyx, INC. | $56.51 | 2023-2024 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $53.20 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $45.19 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $44.41 | 2021-2023 | |
| Qol Medical, LLC | $43.56 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $40.07 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $37.09 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $36.49 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $20.62 | 2024 | Dificid |
| Shield Therapeutics INC | $20.20 | 2023 | Accrufer |
| Covidien LP | $18.59 | 2019 | |
| Novo Nordisk INC | $17.84 | 2025 | Wegovy |
| Evoke Pharma, INC. | $17.18 | 2024 | |
| Amgen INC. | $15.46 | 2023 | Avsola, Amjevita |
| Alnylam Pharmaceuticals INC. | $14.88 | 2025 | Givlaari |
| Braintree Laboratories, INC. | $14.56 | 2025 | Sutab, Suflave |
| Mallinckrodt Hospital Products INC. | $14.42 | 2023 | Terlivaz |
| Biocon Biologics INC | $14.27 | 2025 | Yesintek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Salvatierra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.